bimatoprost and Alopecia-Areata

Vitiligo and alopecia areata (AA) are common autoimmune conditions characterized by white spots on the skin (vitiligo) and bald spots on the scalp (AA), which significantly impact patients' lives by damaging their appearance and function. Melanocytes are the target of immune destruction in vitiligo and are hypothesized to be the site of immune attack in AA. This inflammatory process can be partially reversed by immunosuppressive drugs. Both conditions demonstrate regenerative components that are just now being identified. In this review, we focus on the regenerative medicine aspects of vitiligo and AA, using experimental data from human, mouse, and in vitro models, summarizing the key pathways involved in repopulation of the epidermis with melanocytes in vitiligo and in regrowth of hair follicles in AA. We also discuss treatments that may activate these pathways. Of the regenerative treatments, JAK inhibitors and bimatoprost stimulate repopulation of depleted cells in both diseases, intralesional injections of autologous concentrated platelet-rich plasma and minoxidil showed some benefit in AA, and phototherapy with narrowband UVB was shown to be effective especially in vitiligo. Finally, we discuss future treatments based on the mobilization of stem cells to regenerate anagen hair follicles in AA and intraepidermal melanocytes in vitiligo.

Topics: Alopecia Areata; Animals; Bimatoprost; Cell Movement; Cell Self Renewal; Guided Tissue Regeneration; Hair Follicle; Humans; Janus Kinase Inhibitors; Melanocytes; Mice; Phototherapy; Regenerative Medicine; Vitiligo

Topics: 11-beta-Hydroxysteroid Dehydrogenases; Alopecia Areata; Anthralin; Bimatoprost; Cyclopropanes; Dermatologic Agents; Drug Therapy, Combination; Eyebrows; Eyelashes; Facial Dermatoses; Humans; Latanoprost; Minoxidil; Photosensitizing Agents; Prostaglandins F, Synthetic

Alopecia areata (AA) is a challenging disease with variable treatment outcomes. Hair follicles express vitamin D receptors. Therefore, vitamin D3 may be promising for AA treatment through immunomodulatory mechanisms. The efficacy of bimatoprost in scalp AA treatment was reported by few studies.. To evaluate the efficacy and safety of microneedling (MN) with topical vitamin D3 versus MN with bimatoprost in comparison with MN alone in the treatment of localized AA.. Seventy-five patients with localized AA were divided into three groups. The first group: 25 patients were treated with MN alone. The second group: 25 patients treated with MN combined with topical vitamin D3. The third group: 25 patients treated with MN combined with bimatoprost solution. The response was evaluated clinically and dermoscopically.. At the end of the study, all groups showed a statistically significant decrease in the SALT score compared to the baseline. The clinical response (regrowth scale): vitamin D and bimatoprost groups showed a statistically significant higher regrowth scale compared to MN alone group (p-value = 0.000). After treatment, hair regrowth was significantly higher in MN combined with bimatoprost than in MN combined with topical vitamin D3. However, after 3 months of follow-up, there was no statistically significant difference between both groups. Side effects were mild and transient in all groups.. Topical vitamin D3 and bimatoprost combined with MN are safe and effective therapeutic options for localized AA.

Topics: Administration, Topical; Alopecia Areata; Bimatoprost; Cholecalciferol; Combined Modality Therapy; Dermatologic Agents; Dry Needling; Hair; Humans; Treatment Outcome

Alopecia areata (AA) is an immune-mediated disease that targets anagen hair follicles. Despite various therapeutic options, there is no cure for AA. Prostaglandin analogues have been recognized as being capable of inducing hypertrichosis.. To compare the efficacy and safety of bimatoprost to those of corticosteroid in the treatment of scalp AA.. Thirty adult patients with patchy AA (S1) were included. Two AA patches were randomly assigned to treatment either by mometasone furoate 0.1% cream once daily (area A) or bimatoprost 0.03% solution twice daily (area B) for 3 months. Patients were assessed using the Severity of Alopecia Tool (SALT) scoring system for hair re-growth.. All responding AA patches showed significant reduction in their SALT score after therapy. Area B demonstrated significantly better results regarding rapidity of response in weeks, percentage of hair re-growth and side effects compared to area A.. Bimatoprost solution represents a therapeutic option for scalp AA.

Topics: Administration, Cutaneous; Adult; Alopecia Areata; Bimatoprost; Dermatologic Agents; Female; Hair; Humans; Male; Middle Aged; Mometasone Furoate; Pilot Projects; Prospective Studies; Scalp; Severity of Illness Index; Single-Blind Method; Skin Cream; Young Adult

Topics: Administration, Topical; Alopecia Areata; Amides; Antihypertensive Agents; Bimatoprost; Cloprostenol; Eyelashes; Humans; Latanoprost; Prostaglandins F, Synthetic; Treatment Failure

Topics: Adult; Alopecia Areata; Amides; Antihypertensive Agents; Bimatoprost; Cloprostenol; Eyelashes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions

Bimatoprost is a synthetic prostaglandin structural analogue used among other indications to increase eyelash growth. The aim of this prospective, open-label study was to evaluate the safety and efficacy of topical bimatoprost in the treatment of eyelash loss in alopecia areata totalis (AT) and universalis (AU). Study subjects applied ophthalmic bimatoprost (0.3 mg/ml) solution to the eyelid margins once nightly for at least 12 weeks (mean treatment period was 30.6 weeks). A total of 16 out of 17 subjects completed the study. Only the subjects with eyelashes present at baseline experienced an increase in eyelash length and thickness. No new eyelash regrowth was induced. In patients with AT and AU topical bimatoprost affected existing eyelashes, but failed to induce regrowth of new eyelashes.

Topics: Alopecia; Alopecia Areata; Bimatoprost; Eyelashes; Humans; Prospective Studies

Alopecia areata (AA) is a genetic and immune-mediated disease that targets anagen hair follicles. Despite limited evidence supporting the efficacy of corticosteroid treatments, they are often prescribed as first-line therapy because of their favorable safety profile. Prostaglandin analogues are currently being studied as an alternate therapy for scalp AA in adults. Herein we present a case of steroid-resistant multifocal AA that was successfully treated with topical bimatoprost.

Topics: Administration, Topical; Alopecia Areata; Antihypertensive Agents; Bimatoprost; Child; Female; Humans

Topics: Adolescent; Alopecia Areata; Amides; Bimatoprost; Cloprostenol; Dermatologic Agents; Eyelashes; Eyelid Diseases; Female; Humans